Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BIIB023- low dose Dose · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Chinese Subjects - low dose BIIB023 IV | EXPERIMENTAL | - |
| Chinese Subjects - high dose BIIB023 IV | EXPERIMENTAL | - |
| Japanese Subjects - low dose BIIB023 IV | EXPERIMENTAL | - |
| Japanese Subjects - high dose BIIB023 IV | EXPERIMENTAL | - |
| Causasian Subjects - low dose BIIB023 IV | EXPERIMENTAL | - |
| Caucasian Subjects - high dose BIIB023 IV | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BIIB023 - low dose IV Dose | DRUG | - |
| BIIB023 - high dose IV Dose | DRUG | - |
Inclusion Criteria: * Must have the ability to understand the purpose and risks of the study \& provide signed \& dated informed consent. * Chinese, Japanese or Caucasian subjects * Subjects of childbearing potential must practice effective contraception during the study and 3 months after their la...
BIIB023 is an investigational monoclonal antibody being studied for use in rheumatoid arthritis and in healthy volunteers. It has been evaluated in Phase 1 clinical trials for these conditions, though it is not approved and remains in clinical development.
BIIB023 is an anti-TWEAK monoclonal antibody, meaning it targets the cytokine TWEAK. It was studied in a Phase 1 trial in subjects with rheumatoid arthritis to assess its effects, though no efficacy data from that trial is available here.
BIIB023 is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker BIIB. Biogen has sponsored the clinical trials of BIIB023 in rheumatoid arthritis and healthy volunteer studies.
BIIB023 is in Phase 1 clinical development. All three completed trials of BIIB023 were Phase 1 studies, including trials in rheumatoid arthritis and healthy volunteers. It is investigational and has not been approved by regulatory authorities.
BIIB023 has been studied in three completed Phase 1 trials: NCT00771329 in rheumatoid arthritis, NCT01407406 in healthy volunteers of different ethnicities, and NCT01943513 in healthy male volunteers for muscle atrophy. All trials are completed.
BIIB023 is an anti-TWEAK monoclonal antibody, and the trial NCT00771329 is titled 'BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis.' This indicates BIIB023 is the drug being evaluated as an anti-TWEAK agent in that study.